-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Corvus Pharma, Raises Price Target to $27

Benzinga·01/20/2026 17:41:10
Listen to the news
HC Wainwright & Co. analyst Sean Lee maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from $11 to $27.